Charles Schwab Investment Management Inc. Purchases 157,135 Shares of Immunome, Inc. $IMNM

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Immunome, Inc. by 34.4%, owning 614,387 shares valued at approximately $4.13 million.
• Institutional investors currently hold 44.58% of Immunome's stock, with several other firms also increasing their positions recently.
• Eight research analysts have rated Immunome with a Buy rating and an average price target of $22.50, indicating positive market sentiment toward the company.

Charles Schwab Investment Management Inc. increased its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 34.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 614,387 shares of the company's stock after buying an additional 157,135 shares during the period. Charles Schwab Investment Management Inc. owned 0.71% of Immunome worth $4,135,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in IMNM. BNP Paribas Financial Markets bought a new position in Immunome during the fourth quarter worth $70,000. Tower Research Capital LLC TRC boosted its position in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares during the period. Aquatic Capital Management LLC bought a new position in Immunome during the fourth quarter worth $95,000. ANTIPODES PARTNERS Ltd bought a new position in Immunome during the first quarter worth $95,000. Finally, KLP Kapitalforvaltning AS boosted its position in Immunome by 140.8% during the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock worth $115,000 after purchasing an additional 10,000 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Stock Up 10.5%

Shares of Immunome stock traded up $0.97 during trading on Wednesday, reaching $10.25. The company's stock had a trading volume of 1,061,336 shares, compared to its average volume of 627,134. The business's 50-day moving average price is $9.83 and its 200-day moving average price is $8.85. The firm has a market cap of $892.16 million, a PE ratio of -3.33 and a beta of 1.92. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $16.73.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. The company had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. Equities analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Ratings Changes

IMNM has been the subject of a number of research analyst reports. Evercore ISI initiated coverage on shares of Immunome in a research report on Friday, August 22nd. They set an "outperform" rating and a $18.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Wedbush reaffirmed an "outperform" rating and set a $21.00 price objective on shares of Immunome in a research report on Thursday, August 7th. Finally, Guggenheim reaffirmed a "buy" rating and set a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $22.50.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.